Given that both PCNA and PARP1 are closely linked to DNA replication stress and repair, investigating the molecular mechanism of PCNA in regulating DNA damage repair and the regulatory relationship between PCNA and PARP1 can not only provide a novel strategy for targeted therapy of HCC but also expand the clinical indication of PARP inhibitors. This evidence concerns the gene PARP1 and hepatocellular carcinoma.